The DIAN-TU acknowledges the many individuals who have contributed to the DIAN-TU Trials including funding partners, leadership team, core leaders, project arm leaders, study sites and institutional study partners listed in the following pages. ***All manuscripts should include one of the following statements of acknowledgement of the DIAN-TU Team located at DIAN.wustl.edu***.

General DIAN-TU and/or DIAN-TU Trial Platform (not drug specific or all drugs):

The DIAN-TU is supported by the Alzheimer's Association, GHR Foundation, an anonymous organization, and the DIAN-TU Pharma Consortium (https://dian.wustl.edu/our-research/the-pharma-consortium/). The DIAN-TU-001 Trial has received support from the Alzheimer's Association, Eli Lilly and Company, Roche, Janssen Pharmaceuticals, NIH U01AG042791, NIH U01AG042791-S1 (FNIH and Accelerating Medicines Partnership), NIH R1AG046179, NIH R01/R56 AG053267, NIH R01AG53267-S1, NIH R01AG53267-S2, Avid Radiopharmaceuticals, GHR Foundation, and an anonymous organization. In-kind support has been received from CogState and Bracket. We acknowledge the altruism of the participants and their families and contributions of the DIAN and DIAN-TU research and support staff at each of the participating sites (https://dian.wustl.edu/wp-content/uploads/2019/04/DIAN-TU-Publications_Acknowledgement_V26.pdf) for their contributions to this study.

DIAN-TU Trial Platform - Sola/Gant specific:

The DIAN-TU is supported by the Alzheimer's Association, GHR Foundation, an anonymous organization, and the DIAN-TU Pharma Consortium (https://dian.wustl.edu/our-research/the-pharma-consortium/). This research for the DIAN-TU-001 Trial has received support from the Alzheimer's Association, Eli Lilly and Company, Roche, NIH U01AG042791, NIH U01AG042791-S1 (FNIH and Accelerating Medicines Partnership), NIH R1AG046179, NIH R01AG53267-S1, Avid Radiopharmaceuticals, GHR Foundation, and an anonymous organization. In-kind support has been received from CogState and Bracket. We acknowledge the altruism of the participants and their families and contributions of the DIAN and DIAN-TU research and support staff at each of the participating sites (https://dian.wustl.edu/wp-content/uploads/2019/04/DIAN-TU-Publications_Acknowledgement_V26.pdf) for their contributions to this study.

DIAN-TU Trial Platform – Atabecestat specific:

The DIAN-TU is supported by the Alzheimer's Association, GHR Foundation, an anonymous organization, and the DIAN-TU Pharma Consortium (https://dian.wustl.edu/our-research/the-pharma-consortium/). This research for the DIAN-TU-001 Trial has received support from the Alzheimer's Association, Janssen Pharmaceuticals, NIH R01/R56 AG053267, NIH R01AG53267-S1, GHR Foundation, and an anonymous organization. We acknowledge the altruism of the participants and their families and contributions of the DIAN and DIAN-TU research and support staff at each of the participating sites (https://dian.wustl.edu/wp-content/uploads/2019/04/DIAN-TU-Publications_Acknowledgement_V26.pdf) for their contributions to this study.

Publication Authorship: The overarching considerations for DIAN-TU publications are collaboration and inclusiveness. When studies use DIAN-TU Trial data and/or biospecimens processed by the DIAN-TU Coordinating Center Cores, an invitation to collaborate (meriting authorship) on the manuscript should be issued to respective DIAN-TU Study Team Members as defined below:

DIAN-TU Study Team Members (see complete list of individuals on pages 3-20)

Invite to co-author:

- **Leadership Team**
- **Pharma Partners**
- **Core Leaders (Core leaders may include staff member, fellow, co-investigator)**
- **Site Principal Investigators**

Acknowledge:

- **DIAN-TU Staff**
- **Pharma Teams**
- **Commercial Vendors and Collaborators**
- **DSMB Members**
- **Therapy Evaluation Committee**
- **Clinical Trials Committee**
- **Data Sharing and Communications Committee**
- **DIAN EXR Referring Clinicians and Researchers**
- **DIAN-TU Advisers and Collaborators**

Funding Partners

Through public/private support and partnership, the DIAN-TU has launched trials to provide advancement of treatments, scientific understanding and improvements in the approach to Alzheimer's disease drug developments.

- DIAN-TU Trial Pharma Partners: **Lilly (Solanazemab), Roche (Gantenerumab) and Janssen (BACEi)**
- Alzheimer's Association
- GHR Foundation
- National Institute on Aging of the National Institutes of Health; Accelerating Medicines Partnership (AMP) - ***U01 AG042791, R01 AG046179, R01/R56 AG053267, R13 AG055232***
- DIAN-TU Pharma Consortium: ***Biogen Idec, Eisai, Janssen, Lilly, Roche/Genentech, United NeuroScience*** *(Former Members: Abbvie, Amgen, AstraZeneca, Elan, Forum, Mithridion, Novartis Pharm AG, Pfizer, Sanofi-Aventis)*
- CogState
- Bracket
- Avid Radiopharmaceuticals
- Anonymous Foundation

Leadership Team

Washington University School of Medicine, Department of Neurology

Randall Bateman, MD
Director and Principal Investigator DIAN-TU

Eric McDade, DO
Associate Director, DIAN-TU

David Clifford, MD
Medical Director

Project Arm Leaders

Steve Salloway, MD, Gantenerumab
Butler Hospital

Martin Farlow, MD, Solanazemab
Indiana University

Lon Schneider, MD, BACE
Butler Hospital

Pharma Partners

Eli Lilly	**Hoffman La-Roche**	**Janssen**
John Sims	Greg Klein	Gary Romano
Cheryl Brown	Smilijana Ristic	Hong Sun
Eric Siemers (retired)	Monika Baudler	Luc Tritsman (retired)

DIAN-TU Core Leaders

Randall Bateman, MD
Administrative Core Leader
Washington University School of Medicine

Anne Fagan, PhD
Biomarker Core Leader
Washington University School of Medicine

Chengjie Xiong, PhD
Biostatistics Core Leader
Washington University School of Medicine

Guoqiao Wang, PhD
Biostatistics Co-Core Leader
Washington University School of Medicine

Jason Hassenstab, PhD
Cognition Core Leader
Washington University School of Medicine

Alison Goate, DPhil
Genetics Core Leader
Mt. Sinai School of Medicine

Carlos Cruchaga, PhD
Genetics Core Leader
Washington University School of Medicine

Tammie Benzinger, MD
Imaging Core Leader
Washington University School of Medicine

Rick Perrin, MD
Neuropathology Core Leader
Washington University School of Medicine

Cliff Jack, MD
MRI, Mayo Clinic

Robert Koeppe, MD
PET Imaging, University of Michigan

Nigel Cairns, MD (retired)
Neuropathology Core Leader
Washington University School of Medicine

Peter Snyder, PhD
(Former Cognition Core Leader)
Brown University

DIAN-TU Staff

Administration

Garland Edmonds, Accounting/Purchasing Assistant
Amanda Fulbright, Grant Specialist
Jacki Mallmann, Senior Grant Specialist
Karen McCann, Financial Accounting Assistant
Julie Murphy, Accounting/Purchasing Assistant
Anna Santacruz, Administrative Director
Jeanette Schillizzi – Research Administrator
Shannon Sweeney, Finance Analyst
Linda Watkins-Imhof, Accounting/Purchasing Assistant

Biomarker

Kelley Coalier, Lead Scientist
Matt Amos, Lead Technician
Fatima Amtashar, QC Technician
Sushila Sathyan, Archivist

Clinical Operations

Susan Mills – Director of Clinical Operations
Nicole Kelley - Associate Director of Clinical Operations
Stephanie Belyew - Clinical Research Development Coordinator, Site, Vendor and GCP Management
Angela Fuqua - Clinical Research Development Coordinator, Clinical Scale, Drug Supply and Vendor Management
Annette Stiebel - Clinical Research Development Coordinator
Caryll Bentley - Contract Project Manager
JaNeen Wisner - Contract Project Coordinator
Tayona Mayhew - Data Management Specialist
Zenobia Bridgewater - Clinical Research Coordinator
Erin Cattoor - Research Nurse Coordinator II
Molly Fitzgerald – Clinical Research Study Assistant I
Erica Fowler - Clinical Research Coordinator I
Kurtis Hanks - Clinical Research Coordinator I
Dottie Heller - Research Nurse Coordinator II
Latoya Jones - Clinical Research Coordinator II
Paulette MacDougall - Research Nurse Coordinator II
Michelle Jorke - Clinical Research Coordinator II
Eugene Rubin - QC
Jessi Smith - Senior Clinical Research Coordinator
Marisol Tahan - Clinical Research Coordinator
Mary Wolfsberger - Clinical Research Coordinator

Biostatistics

Yan Li - Co-Investigator
Xu Xiong - Database Manager

Cognition

Andy Aschenbrenner – Research Instructor
Jennifer Smith - Professional Rater III

DIAN Expanded Registry (DIAN EXR)

Eric McDade - Director
Randall Bateman – Associate Director
Jorge Llibre-Guerra – Post-Doctoral Associate
Ellen Ziegemeier - Senior Clinical Research Coordinator
Jennifer Petranek - Clinical Coordinator I
Sarah Adams - Clinical Research Coordinator II
Susan Brandon - Clinical Research Coordinator II

DIAN-TU Post-Doctoral Associate(s)

Jorge Llibre-Guerra – Post-Doctoral Associate

Imaging

Theresa Butler - Research Lab Manager
Lisa Cash - Senior Clinical Research Coordinator
Jon Christensen - Staff Scientist
Aylin Dincer - Research Assistant
Tony Durbin - Senior Clinical Research Coordinator
Shaney Flores - Research Assistant
Karl Friedrichsen - Research Assistant
Brian Gordon - Co-Investigator
Russ Hornbeck - Project Manager
Nelly Joseph-Mathurin - Post-doc
Sarah Keefe - Research Assistant
Lakisha Lloyd - Research Coordinator
Laura Marple - Research Technician II
Austin McCullough - Graduate Research Assistant
Jeanine Portell - Senior Clinical Research Coordinator
Stephanie Schultz - Pre-Doctoral Trainee
Sally Schwarz - Co-Investigator
Yi Su - Co-Investigator
Andrei Vlassenko - Co-Investigator
Qing Wang - Post-doc
Jinbin Xu - Co-Investigator

Neuropathology

Erin Franklin - Research Coordinator
Erin Cattoor - Research Nurse Coordinator II

Eli Lilly Team

John Sims, GBD Leader and Senior Medical Director
Cheryl Brown, COO
Roy Yaari, Senior Medical Advisor
Karen Chilcotte Holdridge, CRS
Isabella Velona, Clinical Trial Project Manager
Scott Andersen, Biostatistician
Michele Mancini, GPS
Brian Willis, PK/PD Project Leader
Sonia Nijampatnam, Pharmaceutical Project Management
Kathryn Broderick, Global Regulatory Affairs
Julie Bush, Product Delivery
Shamrock Garrett, Sr. CTMA
Traci Peddie, Data Sciences & Solutions
Natalie Vantwoud, Data Management
Barbara Lightfoot-Owens, Medical Writer
John Brad-Holmes, Central Lab

Former

Phyllis Ferrell Barkman
Russ Barton
Lauren Brunke
Robert Dean
Deanilee Deckard
Ann Catherine Downing
Ganapathy Goppalrathnam
David Henley
Janice Hitchcock
Tracie Peddie
Melissa Pugh
Tami Jo Rayle
Shiloh Scott
James Senetar
Gopalan Sethuraman
Eric Siemers
Brian Steuenwald
Connie Tong
Jim Vandergriff

Avid

Michael Devous
Erica Elephant
Laura Harper
Marybeth Howlett
Mark Mintun
Michael Pontecorvo

Hoffman-LaRoche Team

Monika Baudler, LifeCycle Leader
Rachelle Doody, Global Head of Neurodegneration
Paul Delmar, Principal Statistical Scientist
Carsten Hofmann, Clinical Pharmacologist
Michaela Jahn, Global Biometrics Team Leader
Geoff Kerchner, Global Development Leader
Gregory Klein, Biomarker Experimental Medicine Leader
Smiljana Ristic, Associate Group Medical Director
Alison Searle, Operations Program Leader
Marco Sonderegger, Technical Development Leader
Roz Sutton, EU Regulatory Partner
Janette Turner, US Regulatory Partner
Jaku Wojtowicz, Safety Science Director
Susan Yule, Global Regulatory Leader

Former

Elizabeth Ashford, Operations Program Leader
Bogdon Balas, Safety Science Leader
Estelle Vester-Blokland, LifeCycle Leader
Stephanie Capo-Chichi, EU Regulatory Partner
David Agnew, Global Study Manager
Ernest Dorflinger, Translational Medicine Leader
Efe Egharevba, Global Study Manager
Christelle Laroche, Technical Development Leader
Isabelle Bauer Dauphin, Technical Development Leader
Rob Lasser, Global Development Leader
Ferenc Martenyi, Global Development Leader
Glenn Morrison, Global Development Leader
Tania Nikolcheva, Biomarker Experimental Medicine Leader
Michael Rabbia, Statistical Scientist
Juha Savola, Project Leader
Janice Smith, Clinical Science Leader
Dietmar Volz, Statistical Scientist

Janssen Team

Caitlin Beatty
Jennifer Bogert
Miranda Damen
Carol Davies
Marisa Ehinger
Suzanne Foy
Monique Franc
Betty Guinter
Katrin Haeverans
Megan Katz
Hartmuth Kolb
Cathy Marseca
Reena Mistry
Sophie Morin
Gary Romano
Maria Schpatschynskyj
Hong Sun
Monika Sulidis
Luc Tritsman

The following should be acknowledged in DIAN-TU Publications

- Commercial Vendors and Collaborators
- DSMB Members
- Therapy Evaluation Committee
- Clinical Trials Committee
- Data Sharing and Communications Committee
- DIAN EXR Referring Clinicians and Researchers
- DIAN-TU Advisers and Collaborators

DIAN-TU Commercial Vendors and Collaborators

IQVIA

Lynne Hughes
Miriana Vankov
Denise Dormody
Ryan Thompson
Frederique Alary
Carla Hancock
Kim Hughes
Eva Irmy
David Margolin, MD
Olja Tanjga, MD
Deitra Wade

Berry Consultants

Scott Berry
Melanie Quintana
Barbara Wendelberger

CogState

Granzer Regulatory Consulting

Cardinal Health Regulatory Sciences

Signat

DIAN-TU DSMB Members

The DSMB is an expert advisory group who functions as a review committee independent from the Sponsor. DSMB members meet without the Sponsor or study team members to review and discuss provided data. The DSMB scope is to review study data to ensure the safety of subjects enrolled in DIAN-TU-001.

Gary Cutter, DSMB Chairperson
Steve Greenberg
Scott Kim
David Knopman
Willis Maddrey (Retired)
Kristine Yaffe
Karl Kieburtz (Retired DSMB Chairperson)
Allan Levey (Retired)

DIAN-TU Data Sharing and Communications Committee

Andy Aschenbrenner, PhD, Committee Chair
Anna Santacruz, Administrative Director

DIAN-TU Therapy Evaluation Committee

The DIAN-TU established a Therapy Evaluation Committee comprised of worldwide experts in AD research and clinical studies from multiple institutions to vet and evaluate compounds nominated for participation in the DIAN-TU trial. Areas of expertise include clinical trials in AD and other diseases, autosomal dominant and sporadic AD, immunotherapy, neurodegenerative disorders, cell and molecular biology of AD, preclinical AD studies, proteomics (AD related proteins), AD neuropathology, cognitive and clinical testing, cerebral amyloid angiopathy, neuroimaging, translational AD trials, and tau biology.

Randall Bateman, MD, Chair, Washington University
Eric McDade, DO, Co-Chair, Washington University
Paul Aisen, MD, Alzheimer's Therapeutic Research Institute *(clinical trials)*
Jasmeer Chhatwal, MD, PhD, MMSc, Massachusetts General Hospital, Harvard Medical School *(imaging)*
David Clifford, MD, Washington University School of Medicine *(Medical Director, DIAN-TU Trials)*
David Cribbs, MD, UC Irvine *(immunotherapy)*
Nick Fox, MD, FRCP, FMedSci, Dementia Research Centre (genetics)
Serge Gauthier, Serge Gauthier, CM, MD, FRCPC, Director, AD & Related Disorders Unit
McGill Centre for Studies in Aging (clinical trials)
David Holtzman, MD, Washington University School of Medicine *(neurodegeneration, animal models)*
Matthias Jucker, PhD, Hertie Institute for Clinical Brain Research *(translational AD)*
Jeff Kelly, MD, Scripps *(proteomics)*
Virginia Lee, PhD, University of Pennsylvania, Perelman School of Medicine *(tau biology)*
Simon Mead, FRCP, PhD, Institute of Prion Diseases (genetics)
Cath Mummery, PhD, FRCP, Dementia Research Centre (genetics)
Erik Musiek, MD, PhD, Washington University School of Medicine *(translational AD)*
Erik Roberson, MD, PhD, University of Alabama *(tau proteins)*
Mathias Staufenbiel, PhD, Hertie Institute for Clinical Brain Research, Tubingen *(pre-clinical and clinical AD studies)*
Robert Vassar, PhD, Northwestern *(cell and molecular biology)*

Former TEC Members
Bart DeStrooper, PhD, VIB, K.U. Leuven, Germany
William Klunk, MD, PhD, University of Pittsburgh, Pennsylvania
Cynthia Lemere, MD, Brigham and Women's Hospital, Boston, Massachusetts
John C. Morris, MD, Washington University School of Medicine, St. Louis, Missouri

Clinical Trials Committee (CTC) Members

Randall Bateman, Washington University in St. Louis School of Medicine
John Morris, Washington University in St. Louis School of Medicine
Chengjie Xiong, Washington University in St. Louis School of Medicine
Denise Heinrichs, DIAN Family Representative
John Ringman University of California, Los Angeles
Laurie Ryan, Division of Science, National Institute on Aging
Neil Buckholtz, National Institute on Aging
Reisa Sperling, Director, Center for Alzheimer Research and Treatment
Stephen Salloway, Butler Hospital
Paul Aisen, University of California, San Diego
Anna Santacruz, Washington University in St. Louis School of Medicine
Gabrielle Strobel, Alzheimer Research Forum
Bill Klunk, University of Pittsburgh
William Thies, Alzheimer's Association

CTC Steering Committee Members

Anne Fagan, Washington University in St. Louis School of Medicine
Mark Mintun, Washington University in St. Louis School of Medicine
Natalie Ryan, University College London
Virginia Buckles, Washington University in St. Louis School of Medicine
David Hawver, FDA
Martin Farlow, Indiana University
Maritza Ciliberto, DIAN Family Representative
Ralph Martins, Edith Cowan University
Jennifer Williamson, Columbia University

Study Sites

Argentina

Insituto de Investigaciones Neurologicas Fleni https://www.fleni.org.ar/especialidades/neurologia/neurologia-cognitiva-neuropsicologia-y-neuropsiquiatria/	
Ricardo F. Allegri	Principal Investigator
Patricio Chrem Mendez	Co-Investigator
Lucia Crivelli	Neuropsychologist
Ezequiel Surace	Biologist
Gustavo Sevlever	Neuropathologist
Silvia Vazquez	Imaging Principal Investigator
Luciana Armanini	Study Coordinator

Australia

Neuroscience Research –Sydney (SG, AV)	
William Brooks	Principal Investigator
Michael J Fulham	Imaging Principal Investigator
Jacob Bechara	Study Coordinator
David Foxe	CDR assessments
Australian Alzheimer's Research Foundation – Perth (SG)	
Roger Clarnette	Principal Investigator
Nick Reynders	Imaging Principal Investigator
Paula Mather	Study Coordinator
University of Melbourne – Melbourne (SG, AV)	
Colin Masters	Principal Investigator
Christopher Rowe	Imaging Principal Investigator
Bev Clinch	Study Coordinator
David Baxendale	Back up Coordinator

Brazil

University of São Paulo	
Ricardo Nitrini	Principal Investigator

Legend for site participation:

SG = Solanazemab and Gantenerumab arms; B = BACE; MK = MK6240 Tau; AV = AV1451 Tau; CRI = Cognitive Run-in

Study Sites (continued)

Canada

Douglas Hospital Research Centre (SG, AV)	
Serge Gauthier	Principal Investigator
Pedro Rosa-Neto	Imaging Co-Investigator
Carley Mayhew	Study Coordinator
Laura Robb	Back up Coordinator
Vancouver Coastal Health Authority (SG, AV)	
Robin Hsiung	Principal Investigator
Dan Worsley	Imaging Principal Investigator
Michele Assaly	Study Coordinator
Eloise Nicklin	Back up Coordinator
Sunnybrook Health Science Centre (SG, AV)	
Mario Masellis	Principal Investigator
Katie Sharp	Study Coordinator
Stephanie Hetherington	Back up Coordinator
Universite Laval	
Robert Laforce	Principal Investigator

Colombia

Grupo de Neurociencias Sede de la Universidad de Antioquia	
Francisco Lopera	Principal Investigator
Yakeel Quiroz	Sub-Investigator

Legend for site participation:

SG = Solanazemab and Gantenerumab arms; B = BACE; MK = MK6240 Tau; AV = AV1451 Tau; CRI = Cognitive Run-in

Study Sites (continued)

France

CHU de Rouen (SG, AV) www.alzheimer-genetique.fr	
David Wallon, MD, PhD	Principal Investigator
Didier Hannequin, MD, PhD	Sub-investigator
Alexandre Morin, MD	Sub-Investigator
Aline Zarea, MD	Sub-investigator
Emmanuel Gerardin, MD, PhD	MRI Neuroimaging Investigator
Pierre Bohn, PharmaD	Imaging principal Investigator
Mathieu Chastan, MD	Imaging Sub-Investigator
Pierre Vera, MD, PhD	Imaging Sub-Investigator
Marion Colnot, Pharma D	Hospital Pharmacist
Nathalie Donnadieu, PharmaD	Hospital Pharmacist
Muriel Quillard-Muraine, MD, PhD	Biologist
Celine Bergot	Study Coordinator
Severine Jourdain	Back-up Study Coordinator
Hopital Larrey – Angers (SG)	
Valérie Chauviré, MD	Sub-investigator
Frédérique Etcharry-Bouyx, MD	Sub-investigator
Groupe Hospitalier Pitie (SG, AV)	
Bruno Dubois	Principal Investigator
Marie-Odile Habert	Imaging Principal Investigator
Nadjia Younsi	Back up Coordinator
Hopital Neurologique Pierre Wertheimer– Lyon (SG)	
Maite Formaglio	Principal Investigator
Didier Lebars	Imaging Principal Investigator
Najat El Kfif	Study Coordinator
Aurélie Jullien	Back up Coordinator
CHU de Toulouse (SG, AV)	
Jereme Pariente	Principal Investigator
Pierre Payoux	Imaging Principal Investigator
Claire Thalamas	CID
Amel Driff	CRA
Elsa Pomies	Neuropsychologist
Pascale Gauteul	Study Coordinator

Legend for site participation:

SG = Solanazemab and Gantenerumab arms; B = BACE; MK = MK6240 Tau; AV = AV1451 Tau; CRI = Cognitive Run-in

Study Sites (continued)

France (continued)

Centre Hospitalier Unversitaire - Lille (SG, AV)	
Florence Pasquier	Principal Investigator
Adeline Rollin-Sillaire	Co-Investigator
Franck Semah	Imaging Principal Investigator
Laetitia Breuilh	Study Coordinator
Manon Laforce	Back up Coordinator
Michael Bottlaender, MD, PhD	Imaging Principal Investigator
Orsay Imaging	
Michael Bottlaender, MD, PhD	Imaging Principal Investigator

Germany

German Center for Neurodegenerative Diseases (DZNE), Universitaetsklinikum Tuebingen	
Christoph Laske	Principal Investigator
Ludwig-Maximilians-Universität	
Johannes Levin	Principal Investigator
Adrian Danek	Principal Investigator (retired)
Jonathan Vöglein	Co-Investigator
Igor Yakushev	Imaging Principal Investigator
Siri Houeland di Bari	Study Coordinator

Ireland

St. Vincent's University Hospital	
Justin Kinsella	Principal Investigator
Gillian O'Boyle	Study Coordinator

Italy

Azienda Ospedaliera Universitaria Careggi	
Sandro Sorbi	Principal Investigator
IRCCS Centro San Giovanni di Dio Fatebenefratelli	
Giovanni Frisoni	Principal Investigator
Sara Gipponi	Study Coordinator
Michela Rampini	Study Coordinator
Anna Mega	Genetic Counseling
Emilio Di Maria, MD	Geneticist
Samantha Galluzzi, MD	Geriatrician
Amalia Cecilia Bruni	Neurologist
Nicoletta Smirne	Statistician
Valentina Laganà	Psychologist
Fabrizio Tagliavini	Neurologist
Cristina Muscio	Psychologist
Alessandro Padovani	Neurologist
Barbara Borroni	Neurologist
Elio Scarpini	Neurologist
Gabriella Salvini Porro	President, Federazione Alzheimer Italia

Legend for site participation:

SG = Solanazemab and Gantenerumab arms; B = BACE; MK = MK6240 Tau; AV = AV1451 Tau; CRI = Cognitive Run-in

Study Sites (continued)

Mexico

Instituto Nacional de Neurologica y Neurocirugla	
Ana Luisa Sosa	Principal Investigator
Longoria Mariana	Co-Investigator

Netherlands

Amsterdam University Medical Centers	
Phillip Scheltens	Principal Investigator

Spain

Hospital Clinic I Provincial de Barcelona (SG, B, AV)	
Raquel Sanchez-Valle	Principal Investigator
Mircea Balasa	Co-Investigator
Albert Lladó	Co-Investigator
Beatriz Bosch	Study Coordinator
Nuria Bargalló	Imaging Co-Investigator
Ignacio Banzo	Imaging Co-Investigator
Andres Perisinotti	Imaging Principal Investigator

United Kingdom

University College London Hospital (SG)	
Catherine Mummery	Principal Investigator
Irfan Kayani	Imaging Principal Investigator
Jane Douglas	Study Coordinator
Miguel Grilo	Co-Investigator

Legend for site participation:

SG = Solanazemab and Gantenerumab arms; B = BACE; MK = MK6240 Tau; AV = AV1451 Tau; CRI = Cognitive Run-in

Study Sites (continued)

United States

Washington University, St. Louis, Missouri (SG, B, AV, MK)	
Barbara J. Snider, MD	Principal Investigator
Tammie Benzinger, MD	Imaging Principal Investigator
Wendy Sigurdson, RN	Study Coordinator
Tamara Donahue, RN	Study Coordinator
Peggy Kelly, RN	Study Coordinator
Emory University, Atlanta, Georgia (SG, B, AV, MK)	
James Lah	Principal Investigator
Carolyn Meltzer	Imaging Principal Investigator
Gail Schwartz	Study Coordinator
Phyllis Vaughn	Study Coordinator
Lydia Piendel	Study Coordinator
University of Pittsburgh, Pennsylvania (SG, B, AV, MK)	
Sarah Berman	Principal Investigator
James Mountz	Imaging Principal Investigator
Lori Macedonia	Study Coordinator
Snezana Ikonomovic	Back up Coordinator
Sarah Goldberg, M.S.	Neuropsychometrist
Elise Weamer, MPH	Neuropsychometrist
James Ruskiewiecz, BS	PET Research Manager
Steven Hegedus	MR Research Assistant
Lee Tarr	MR Research Technologist
Tom Potter	MR Research Technologist
Gina Valetti	MR Research Technologist
University of Alabama at Birmingham (SG, B, AV, MK)	
Erik D. Roberson	Principal Investigator
David S. Geldmacher	Co-Investigator
Marissa Natelson Love	Co-Investigator
Amber Watkins	Study Coordinator
Loren Ashley	Back up Coordinator
Indiana University (SG, B, AV, MK)	
Jared R. Brosch, M.D.	Principal Investigator
Brand Mathews, M.D.	Former Principal Investigator
Arlene Kohn	Study Coordinator
Nancy McClaskey, RN	Study Coordinator
Jill Buck, RN	Study Coordinator
James Fletcher	Imaging Principal Investigator
Butler Hospital, Providence, Rhode Island (SG, B, AV, MK)	
Ghulam Surti	Principal Investigator
Richard Noto	Imaging Principal Investigator
Courtney Bodge	Study Coordinator
William Menard	Back up Coordinator

Legend for site participation:

SG = Solanazemab and Gantenerumab arms; B = BACE; MK = MK6240 Tau; AV = AV1451 Tau; CRI = Cognitive Run-in

Study Sites (continued)

United States

University of Puerto Rico (SG, B, AV, MK)	
Ivonne Z. Jimenez Velazquez	Principal Investigator
Janice Diaz	Study Coordinator
Karen Aleman	Study Coordinator

Yale University, New Haven, Connecticut (SG, B, AV, MK)	
Christopher Van Dyck	Principal Investigator
Ming-Kai Chen	Imaging Principal Investigator
Nina Diepenbrock	Study Coordinator
Adam Mecca, MD, PhD	Sub-Investigator
Susan Good, APRN	Study Nurse

University of California, San Diego (SG, B, AV, MK)	
Doug Galasko	Principal Investigator
Carl Hoh	Imaging Principal Investigator
Dan Szpak	Study Coordinator
Shawnees Peacock	Back up Coordinator

University of Washington (SG, B, AV, MK)	
Suman Jayadev	Principal Investigator
David Lewis	Imaging Principal Investigator
Yeung Tuttero	Study Coordinator

Advocate Lutheran General Hospital, Park Ridge, Illinois	
Darren Gitelman	Principal Investigator
Victoria Begoun	Study Coordinator
Evelyn Torres	Back up Coordinator

AUSC Keck School of Medicine, Los Angeles, California	
Sonia Pawluczyk	Principal Investigator

Columbia University, New York City (SG, B, AV, MK)	
Lawrence Honig	Principal Investigator
Chaitanya Divgi	Imaging Principal Investigator
Ruth B. Tejeda	Rater
Solciris A. Dominguez	Rater
Katrina Cuasay	Rater
Evelyn Dominquez-Rivera	Study Coordinator

Kerwin Research Center, Dallas, Texas	
Diana Kerwin	Principal Investigator
Micah Eimberbrink, PhD	Head of Research Operations

Legend for site participation:

SG = Solanazemab and Gantenerumab arms; B = BACE; MK = MK6240 Tau; AV = AV1451 Tau; CRI = Cognitive Run-in

DIAN EXR Referring Clinicians and Researchers

Neelum T. Aggarwal, MD, Rush University Medical Center, Chicago IL
Tom Ala, Center for Alzheimer's Disease and Related Disorders, Southern Illinois University School of Medicine
Thomas Bird, University of Washington
Sandra E. Black, Sunnybrook Health Sciences Centre, University of Toronto
William J. Burke, MD, Banner Alzheimer's Institute
Cynthia M. Carlsson, MD, MS, University of Wisconsin School of Medicine and Public Health
Andrew Frank M.D. B.Sc.H. F.R.C.P.(C), Bruyere Continuing Care, Ottawa, Ontario, Canada
James E. Galvin, MD, MPH, Charles E. Schmidt College of Medicine, Florida Atlantic University
Alvin C Holm, MD, Bethesda Hospital, St. Paul, MN
John S.K. Kauwe, Brigham Young University
David Knopman MD, Mayo Clinic, Rochester MN
Sarah Kremen, MD, University of California, Los Angeles
Alan J. Lerner, University Hospitals Cleveland Medical Center
Barry S. Oken, MD, PhD, Oregon Health & Science University
Hamid R. Okhravi, Eastern Virginia Medical School
Ronald C. Petersen, Mayo Clinic
Aimee L. Pierce, MD, University of California Irvine
Marsha J. Polk, MED, University of Texas Health Science Center at San Antonio
John M. Ringman, MD, MS, University Southern California
Sanjeev N. Vaishnavi, MD, PhD, University of Pennsylvania
Sandra Weintraub, Northwestern University Feinberg School of Medicine

DIAN-TU Collaborators and Advisers

John Morris, MD, Senior Advisor
David Holtzman, MD, Senior Advisor
Thomas Bird, MD, University of Washington
Dennis Dickinson, MD, Mayo Clinic, Jacksonville, FL
Peter St. George Hyslop, MD, FRS, FRSC, FRCPC, University of Toronto
M. Marsel Mesulam, MD, Cognitive Neurology and Alzheimer's Disease Center, Northwestern University
Cornelia Kamp, **MBA,** University of Rochester

ADCS

Ron Thomas, PhD
Paul Aisen, MD